Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype

Hepatology. 2010 Dec;52(6):2243-4. doi: 10.1002/hep.23826. Epub 2010 Jun 30.
No abstract available

Publication types

  • Letter
  • Kommentar

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Clinical Trials as Topic / methods*
  • Hepacivirus / genetics
  • Hepatitis C / drug therapy*
  • Hepatitis C / genetics
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Interferons
  • Interleukins / genetics*
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins

Substances

  • Antiviral Agents
  • interferon-lambda, human
  • Interferon alpha-2
  • Interferon-alpha
  • Interleukins
  • Recombinant Proteins
  • Polyethylene Glycols
  • Interferons
  • peginterferon alfa-2b
  • peginterferon alfa-2a